Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	Dec 31, 2025	Dec 31, 2024
Selling, General & Admin	14.68	11.36
Research & Development	76.61	45.76
Operating Expenses	91.29	57.12
Operating Income	-91.29	-57.12
Interest Expense (Income)	-6.18	-7.44
Other Expense (Income)	0.09	0.06
Pretax Income	-85.2	-49.74
Net Income	-85.2	-49.74
Free Cash Flow	-81.83	-48.46
EBITDA	-93.69	-59.73
Depreciation & Amortization	-2.31	-2.55
EBIT	-91.38	-57.18

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).